Teva Pharmaceutical Revenue, Profits - TEVA Quarterly Income Statement

Add to My Stocks
$24.36 $0.47 (1.89%) TEVA stock closing price Sep 21, 2018 (Closing)

Looking at financial statements, along with the Teva Pharmaceutical stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the TEVA stock is bound to reflect the impact of the QOQ decline of -7.19%. Revenue for year 2018 Q2 is $4.7B and has decreased from $5.07B quarter on quarter as is evident when you compare the latest figures in the latest Teva Pharmaceutical profit and loss statement with those of the prior corresponding period. Also see Teva Pharmaceutical assets and Teva Pharmaceutical free cash flow for a complete valuation of TEVA stock.

View and download details of revenue and profits for Teva Pharmaceutical for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Teva Pharmaceutical Revenues or Net Sales
Cost Of Goods Sold (COGS)2.64B2.72B2.92B2.97B2.87B2.81B3.1B2.76B2.16B2.02B
Teva Pharmaceutical Gross Profit
Research & Development Expense290M317M360M545M486M457M684M663M375M389M
Selling General & Admin Expense1.67B326M5.41B1.17B1.56B1.23B1.67B1.78B1.43B1.12B
Income Before Depreciation Depletion Amortization106M1.71B-3.23B928M779M1.14B1.04B355M1.07B1.28B
Depreciation Depletion Amortization120M180M11B-6.1B-900M---
Non Operating Income-236M-271M1.02B-809M-657M-447M-1.06B260M-817M-417M
Interest Expense----------
Teva Pharmaceutical Pretax Income
Provision for Income Taxes-76M46M-1.47B-494M-22M54M57M207M29M228M
Investment Gains Losses8M-74M7M-3M-14M7M-3M2M15M-6M
Other Income----------
Income Before Extraordinaries & Disc Operations-176M1.12B-11.54B595M-5.97B645M-973M412M254M636M
Extraordinary Items & Discontinued Operations----------
Teva Pharmaceutical Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS1.02B1.02B1.02B1.02B1.02B1.02B1.02B984M979M920M
Average Shares used to compute Basic EPS1.02B1.02B1.02B1.02B1.02B1.02B1.02B979M914M913M
Income Before Nonrecurring Items763.55M924M997.1M991.2M1B1.11B1.46B1.33B1.23B1.15B
Income from Nonrecurring Items-939.55M196M-12.53B-396.2M-6.97B-469.12M-2.43B-922.66M-974M-512M
Teva Pharmaceutical Earnings Per Share Basic Net
Teva Pharmaceutical Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.750.910.910.950.991.031.361.281.251.18
Preferred Dividends Acc Pd68.32M62.32M68.97M-------
Dividends Common0.000.0073.47-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Teva Pharmaceutical stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Teva Pharmaceutical revenue chart, implies that the company is growing. It has not been the case with Teva Pharmaceutical. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-176M for TEVA stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the TEVA income statement, one can check the Teva Pharmaceutical historical stock prices to check how the price has moved with time.

Teva Pharmaceutical Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield